We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+7.52%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$126M
AUM Growth
+$6.95M
Cap. Flow
-$1.04M
Cap. Flow %
-0.83%
Top 10 Hldgs %
37.72%
Holding
74
New
9
Increased
25
Reduced
7
Closed
17

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$3.42M
2
BIB icon
ProShares Ultra NASDAQ Biotechnology
BIB
+$1.55M
3
INFI
Infinity Pharmaceuticals, Inc.
INFI
+$1.03M
4
PCRX icon
Pacira BioSciences
PCRX
+$949K
5
ARRY
Array Biopharma Inc
ARRY
+$886K

Top Sells

Rank Stock Value
1
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$4.15M
2
PCYC
PHARMACYCLICS INC
PCYC
+$3.48M
3
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$1.73M
4
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$912K
5
TENX icon
Tenax Therapeutics
TENX
+$812K

Sector Composition

Rank Sector Weight
1 Healthcare 82.86%
2 Miscellaneous 16.89%
3 Financials 0.25%
4 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KBIO
51
DELISTED
KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE)
KBIO
$358K 0.28%
93,308
– –
NHLD
52
DELISTED
National Holdings Corporation
NHLD
$321K 0.25%
89,530
– –
JUNO
53
DELISTED
Juno Therapeutics, Inc.
JUNO
$267K 0.21%
+5,000
New +$265K
ARRY
54
CALL
DELISTED
Array Biopharma Inc
ARRY
$135K 0.11%
+2,000
New +$14.8K
JUNO
55
PUT
DELISTED
Juno Therapeutics, Inc.
JUNO
$49K 0.04%
+50
New +$2.65K
NEPT
56
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
– –
0
– –
ADVM
57
DELISTED
Adverum Biotechnologies
ADVM
– –
-1,000
Closed -$405K
AGIO icon
58
Agios Pharmaceuticals
AGIO
$2.05B
– –
-5,000
Closed -$472K
BLUE
59
DELISTED
bluebird bio
BLUE
– –
-463
Closed -$725K
KPTI icon
60
Karyopharm Therapeutics
KPTI
$44M
– –
-1,000
Closed -$459K
LITS
61
Lite Strategy Inc
LITS
$34M
– –
-1,500
Closed -$54K
MGNX icon
62
MacroGenics
MGNX
$260M
– –
-15,000
Closed -$471K
OMER icon
63
Omeros
OMER
$1.39B
– –
-20,000
Closed -$441K
TENX icon
64
Tenax Therapeutics
TENX
$82M
– –
-8
Closed -$812K
XNCR icon
65
Xencor
XNCR
$2.15B
– –
-44,698
Closed -$685K
EIGR
66
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-94
Closed -$803K
MRTX
67
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-25,000
Closed -$733K
OTIC
68
DELISTED
Otonomy, Inc.
OTIC
– –
-12,000
Closed -$424K
AERI
69
DELISTED
Aerie Pharmaceuticals
AERI
– –
-20,000
Closed -$627K
MNTA
70
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
– –
-60,000
Closed -$912K
GEVA
71
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
– –
-17,700
Closed -$1.73M
PCYC
72
DELISTED
PHARMACYCLICS INC
PCYC
– –
-13,600
Closed -$3.48M
SLXP
73
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
– –
-24,000
Closed -$4.15M
1 2
3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q2 2015 Portfolio in Review

As of Q2 2015, Opus Point Partners Management held 74 positions worth $126M, up 5.8% from $119M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Opus Point Partners Management's Q2 2015 filing shows 9 new, 25 increased, 7 reduced and 17 closed positions. Its largest new stake was AstraZeneca: 50,000 shares worth $3.19M. The largest sale was SALIX PHARMACEUTICALS LTD DEL, an estimated $4.15M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 78% a quarter earlier, followed by Miscellaneous and Financials.

  • Opus Point Partners Management's largest Q2 2015 buy was AstraZeneca: 50,000 shares worth $3.19M.
  • Opus Point Partners Management added most to ProShares Ultra NASDAQ Biotechnology in Q2 2015, an estimated $1.55M increase.
  • Opus Point Partners Management's biggest Q2 2015 reduction was Clovis Oncology, Inc., cutting an estimated $307K.
  • Opus Point Partners Management fully exited SALIX PHARMACEUTICALS LTD DEL in Q2 2015, selling an estimated $4.15M.
  • Opus Point Partners Management's ten largest holdings make up 38% of its $126M portfolio in Q2 2015.
  • Opus Point Partners Management opened 9 new positions and closed 17 in Q2 2015.
  • Opus Point Partners Management's portfolio value rose 5.8% quarter-over-quarter to $126M.

Based on Opus Point Partners Management's 13F filing for Q2 2015, filed 14 Aug 2015.